Zacks Investment Research upgraded shares of Bayer AG (NASDAQ:BAYRY) from a hold rating to a buy rating in a research report report published on Tuesday morning. They currently have $148.00 price target on the stock.
According to Zacks, “Bayer surpassed earnings estimates but missed revenue estimates in the second quarter of 2017. The company experienced a significant decline in sales and earnings in the Crop Science segment due to high channel inventories in Brazil. Business at Consumer Health decreased, primarily due to the difficult market environment in the U.S. Based on this, the company lowered its revenue and earnings outlook for 2017. The company is facing generic threats/competition for many of its products including the Yaz franchise (oral contraceptives). The genericization of key drugs would negatively impact revenues. Nevertheless, the company is looking forward to acquire Monsanto Company in a deal worth approximately $66 billion. With the acquisition, the combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. Yet, Bayer’s shares have outperformed the Zacks classified industry year to date.”
Separately, Berenberg Bank cut Bayer AG from a buy rating to a hold rating in a research note on Monday, July 3rd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $148.00.
Bayer AG (NASDAQ:BAYRY) opened at 33.03 on Tuesday. Bayer AG has a 52-week low of $32.90 and a 52-week high of $139.04.
Bayer AG (NASDAQ:BAYRY) last released its earnings results on Thursday, July 27th. The company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.87 by $0.12. Bayer AG had a return on equity of 13.03% and a net margin of 10.90%. The business had revenue of $13.41 billion during the quarter, compared to analysts’ expectations of $14.45 billion. On average, equities analysts expect that Bayer AG will post $2.24 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/bayer-ag-bayry-rating-increased-to-buy-at-zacks-investment-research/1661890.html.
About Bayer AG
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with our FREE daily email newsletter.